SCHEMBL23461024

SCHEMBL23461024

COC(=O)c1ccc(COc2c(C(=O)N[C@H](C(=O)O)C(C)(C)C)ccc3ccccc23)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CXCR2 P25025 3/20 0.48
SMN1; SMN2 Q16637 2/20 0.45
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
LMNA P02545 4/20 0.42
HPGD P15428 1/20 0.42
MAPT P10636 5/20 0.41
ALDH1A1 P00352 3/20 0.41
GAA P10253 2/20 0.41
KDM4E B2RXH2 1/20 0.41
MAPK1 P28482 1/20 0.41
HTT P42858 1/20 0.41
HDAC3 O15379 1/20 0.40
HDAC4 P56524 1/20 0.40
HDAC1 Q13547 1/20 0.40
HDAC7 Q8WUI4 1/20 0.40
HDAC2 Q92769 1/20 0.40
HDAC10 Q969S8 1/20 0.40
HDAC11 Q96DB2 1/20 0.40
HDAC8 Q9BY41 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23461026 1.00 CXCR2 (0.48) CXCR2SMN1; SMN2MEN1KMT2ALMNA
SCHEMBL23461027 0.88 CXCR2 (0.49) CXCR2SMN1; SMN2MEN1KMT2ALMNA
SCHEMBL23461031 0.88 CXCR2 (0.49) CXCR2SMN1; SMN2MEN1KMT2ALMNA
SCHEMBL23460777 0.87 CXCR2 (0.51) CXCR2SMN1; SMN2LMNAMAPTALDH1A1
SCHEMBL23460779 0.87 CXCR2 (0.51) CXCR2SMN1; SMN2LMNAMAPTALDH1A1
SCHEMBL25548737 0.86 CXCR2 (0.64) CXCR2SMN1; SMN2LMNAMAPTALDH1A1
SCHEMBL25549891 0.86 CXCR2 (0.64) CXCR2SMN1; SMN2LMNAMAPTALDH1A1
SCHEMBL23460879 0.86 LMNA (0.51) CXCR2SMN1; SMN2MEN1KMT2ALMNA
SCHEMBL23460884 0.86 LMNA (0.51) CXCR2SMN1; SMN2MEN1KMT2ALMNA
SCHEMBL38147031 0.86 LMNA (0.51) CXCR2SMN1; SMN2MEN1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12630498-B2 Arylamides and methods of use thereof GENZYME CORPORATION (US) 2026-05-19 US disclosed
US-20230159438-A1 ARYLAMIDES AND METHODS OF USE THEREOF GENZYME CORPORATION 2023-05-25 US disclosed
US-20230159438-A1 ARYLAMIDES AND METHODS OF USE THEREOF GENZYME CORPORATION 2023-05-25 US disclosed
US-20230159438-A1 ARYLAMIDES AND METHODS OF USE THEREOF GENZYME CORPORATION 2023-05-25 US disclosed
WO-2021113806-A1 ARYLAMIDES AND METHODS OF USE THEREOF GENZYME CORPORATION (US) 2021-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159438-A1 ARYLAMIDES AND METHODS OF USE THEREOF CFTR, AADAC, ARSA CXCR2 1205/4885SMN1; SMN2 2207/4885MEN1 4477/4885
US-12630498-B2 Arylamides and methods of use thereof CFTR, CLIC1, CLCN2 CXCR2 63/4885SMN1; SMN2 2901/4885MEN1 4414/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.